Verily Health Secures New Funding from NVIDIA and CU Healthcare Innovation Fund
Yahoo Finance ·
On September 9, 2026, Verily Health announced it has obtained fresh capital from NVIDIA, extending its March funding round. Existing backer CU Healthcare Innovation Fund II also contributed additional investment. Alphabet, Series X Capital, and UCHealth remain among the company's current supporters. Stephen Gillett, Chairman and CEO of Verily, stated that the financial injection empowers the firm to build a reliable foundation for healthcare, driving artificial intelligence integration across the medical ecosystem. The capital will fuel the expansion of Verily's flagship data and artificial intelligence platform, Verily Pre, as well as its patient engagement solution, Verily Me. This milestone builds upon a collaboration initiated in October 2025, where researchers leveraged NVIDIA technologies—including NeMo, Parabricks, RAPIDS, and B200 GPUs—to develop Forecast 1.0, a model designed to improve long-term health risk prediction through genomics and electronic health record data integration.
AI 시장 분석
Healthcare AI company Verily Health has attracted new investment from NVDA and CU Healthcare Innovation Fund, accelerating its precision medicine AI strategy. This investment is expected to support the expansion of Verily's Pre platform and the growth of patient engagement solutions, driving AI adoption across the healthcare ecosystem. Investors should pay attention to the growth of the healthcare AI market driven by the combination of NVDA's advanced AI technology and Verily's data platform.
상승 영향
- AI — NVDA's new investment in Verily Health and expanded AI collaboration directly increase demand for NVDA's AI infrastructure and GPUs in the healthcare sector.
- Biotech — Verily's precision medicine AI platform expansion is accelerated, improving research efficiency and accuracy in healthcare, such as genomics and Electronic Health Records (EHR) integrated analysis.
DYAX 전담 분석
NVDA's investment in Verily Health can directly increase the adoption of NVDA's hardware and software stacks (such as NeMo, Parabricks, and B200 GPUs) within the healthcare AI ecosystem, leading to expanded related revenues. In particular, the combination of healthcare data and AI infrastructure acts as a key driver accelerating the commercialization of technology in the precision medicine sector.
The bullish scenario is that the expansion of platform adoption directly links to a surge in demand for NVDA's chips and AI libraries, while the bearish scenario is that the pace of platform expansion slows down due to tightened healthcare data regulations. Key monitoring indicators are the institutional adoption rate of the Verily Pre platform and the proportion of NVDA's healthcare sector AI solution revenue.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 31% · Bearish (Short) 69%
410 participants
Related News
- Apple Debuts First Foldable iPhone, Updates iPhone 18 Pro, AirPods and Watch Lineup
- Apple Unveils Its Initial Foldable Smartphone, the iPhone Duo
- Meta Shares Surge 5.14% Following the Launch of AI Agent Muse With Three Pricing Tiers
- Apple's Foldable iPhone Duo Serves as a Crucial Test of Market Power
- Apple Shares Drop 1% Ahead of Highly Anticipated Foldable iPhone Reveal
- OpenAI Scientist Warns of Bioweapons and Grid Attacks as Company Ships GPT-6 Astra
